+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07736(ABHD12 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07736(ABHD12 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

ABHD12 (α/β-hydrolase domain-containing protein 12) is a transmembrane enzyme belonging to the serine hydrolase superfamily. It is encoded by the ABHD12 gene and is primarily expressed in the brain, retina, and immune cells. ABHD12 functions as a lysophosphatidylserine (lyso-PS) lipase, regulating lipid metabolism and endocannabinoid signaling by hydrolyzing bioactive lipids. Mutations in ABHD12 are linked to the rare neurodegenerative disorder PHARC (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataracts), a recessive autosomal disease characterized by neurological and sensory impairments.

ABHD12 antibodies are critical tools for studying the protein's expression, localization, and function in both physiological and pathological contexts. These antibodies are developed using immunogenic peptides or recombinant protein fragments, often validated for applications like Western blotting, immunohistochemistry, and immunofluorescence. Researchers use ABHD12 antibodies to investigate its role in lipid homeostasis, neuroinflammation, and neurodegenerative processes, particularly in PHARC and other disorders involving lysosomal or endocannabinoid dysfunction. Specific epitopes targeted by these antibodies help map functional domains or mutation-prone regions. Recent studies also explore ABHD12's interaction with the endocannabinoid 2-arachidonoylglycerol (2-AG), linking it to neuroprotection and immune modulation. High-quality ABHD12 antibodies are essential for advancing therapeutic research, including drug discovery aimed at modulating ABHD12 activity.